Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-04-19
2009-11-03
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S199000
Reexamination Certificate
active
07612095
ABSTRACT:
Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-αα-dimethyl-benzen⊖eacetic acid Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-αα-dimethyl-benzen⊖eacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.
REFERENCES:
patent: 5877187 (1999-03-01), Orjales et al.
patent: 0 818 454 (1998-01-01), None
Otsuka et al. “Effect of polymorphic . . . ” Chem. Pharm. bull 47(6)852-856 (1999).
Taday et al. “Using terahertz . . . ” J. Pharm. sci. v.92(4) p. 831-838 (2003).
Kirk-Othmer Encyclopedia of Chemical Technology,John Wiley & Sons, Inc., pp. 95-147, Article Online Posting Date: Aug. 16, 2002.
Rowland and Tozer “Clinical pharmacokinetics . . . ” p. 132 (1995).
Corcostegui et al. “Prelinical pharmacology . . . ” Drug R D 6(6) p. 371-384 (2005).
Corcostegui et al. “In vivo pharmacological . . . ” Crug R D 7(4) p. 219-231 (2005).
Cheronis “Semimicro experimental organic chemistry” p. 31-35 (1958).
Muzaffar et al. “Polymorphism and drug availability” J. Phar. 1(1) 59-66 (1979).
Jain et al. “Polymorphisom in pharmacey” Indian Drugs 23(g)315-329 (1986).
Doelker et al. “Crystalline modification . . . ” CA 138:209993 (2002.
Doelker et al. “Physicochemical behavior or active . . . ” CA 132:325872 (2000).
Corcostegui et al. “In vivo pharmacological . . . ” Drug R D 7(4) p. 219-231 (2005).
Lanz “Pharmaceutical powder tecnology . . . ” Basal (2006) p. 1-4.
CMU Pharmaceutical polymorphism, internet print out (2008) p. 1-3.
Berrueta, L.A., “Matrix solid-phase dispersion technique for the determination of a new antiallergic drug, bilastine, in rat faeces”Journal of Chromatography B., 760:185-190 (2001).
International Search Report dated Oct. 31, 2002.
Blanco Fuente Haydee
Bordell Martin Maravillas
Canal Mori Gonzalo
Lucero De Pablo Maria Luisa
Mosquera Pestaña Ramon
Chang Celia
Faes Farma, S.A.
Ostrolenk Faber LLP
LandOfFree
Polymorph of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorph of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorph of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117336